Modafinil for Cancer-Related Fatigue (MODIFY Trial)

"The minimum age for enrollment in this clinical trial is 18, with the maximum age being set at 75."

"This is an inactive trial, as indicated by the information available on clinicaltrials.gov. This study was originally posted on May 1st, 2022 and was most recently edited on April 13th, 2022. There are currently 224 other trials searching for candidates."

"The main goal of this trial, which will take place over the course of a week, is to see how patients respond to the intervention. Additionally, researchers will also be measuring things like patient satisfaction with fatigue levels, any adverse effects experienced during the trial, and changes in cognition scores."

"Modafinil has received a safety score of 3 from our team at Power. This is due to the fact that this medication has progressed to Phase 3 clinical trials, which demonstrates some efficacy and multiple rounds of data supporting safety."

"This trial is currently looking for 40 individuals that suffer from fatigue and are between the ages of 18-75. The most important criteria that applicants must meet are as follows: a) A score of 4 or greater on the Fatigue item of the Edmonton Symptom Assessment System-revised (ESAS-r), b) The ability to understand and communicate in English and/or French, c) The ability to give first-person informed consent, d) A prognosis of at least 3 months, e) Stage III or IV cancer diagnosis, f) Has been off cytotoxic chemotherapy for at least 1 month, g)"